Skip to content

A Study to See Whether Low-Dose Amitriptyline Can Improve Persistent Symptoms in Patients After Achalasia Treatment

Low-Dose Amitriptyline as Adjunct Therapy for Residual Symptoms Following Peroral Endoscopic Myotomy in Achalasia: A Prospective, Open-Label Randomized Controlled Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105705
Enrollment
82
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K220- Achalasia of cardia

Interventions

Intervention1: Esomeprazole and Amitriptyline: Patients will receive Esomeprazole 40 mg once daily, administered 30 minutes before breakfast. Additionally, they will receive Amitriptyline 10 mg orally

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age greater than or equal to 18 years. 2. Residual symptoms defined as an Eckardt score greater than or equal to 3 persisting at least 2 weeks following technically successful POEM. 3. Normal post-POEM Gastrografin swallow with no delay in esophageal clearance at 5 minutes. 4. No evidence of active inflammation or structural obstruction in upper GI endoscopy and manometry.

Exclusion criteria

Exclusion criteria: 1. Active reflux esophagitis Los Angeles grade B, C, or D on endoscopy. 2. Esophageal stricture. 3. Current use of antidepressants, antipsychotics, or other centrally acting medications. 4. History of major psychiatric illness requiring psychotropic medication. 5. Pregnant or lactating women. 6. Known hypersensitivity to tricyclic antidepressants. 7. Cardiac conduction abnormalities, arrhythmias, or baseline QTc prolongation greater than 450 ms.

Design outcomes

Primary

MeasureTime frame
Clinical response, defined as a reduction of 1 point or greater in the total Eckardt score.Timepoint: Clinical response, defined as a reduction of 1 point or greater in the total Eckardt score.

Secondary

MeasureTime frame
1. Eckardt score components: Change in individual components including dysphagia, regurgitation, chest pain, and weight loss. 2. Visceral Sensitivity Index (VSI): Change in VSI score. 3. Psychological symptom scores: Change in PHQ-9 and GAD-7 scores. 4. Adverse effects and Adherence: Incidence and severity of adverse effects related to amitriptyline and treatment adherence assessed by patient self-report and pill count.Timepoint: 12 weeks

Countries

India

Contacts

Public ContactAnand Kumar Raghavendran

Department of Medical Gastroenterology

dranandkumar119@gmail.com9740461517

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026